Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-...

Full description

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 62; no. 8; pp. 1973 - 1981
Main Authors Rosso, Aldana, Juliusson, Gunnar, Lorenz, Fryderyk, Lehmann, Sören, Derolf, Åsa, Deneberg, Stefan, Jädersten, Martin, Antunovic, Petar, Cammenga, Jörg, Möllgård, Lars, Wennström, Lovisa, Ölander, Emma, Ehinger, Mats, Fogelstrand, Linda, Höglund, Martin, Lazarevic, Vladimir Lj
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 2021
Subjects
allogenic stem cell transplantation
AML
Cancer and Oncology
Cancer och onkologi
Clinical Medicine
Hematologi
Hematology
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
MRD
multiparameter flow cytometry
overall survival
AML
allogenic stem cell transplantation
overall survival
multiparameter flow cytometry
MRD
Online AccessGet full text

Cover

More Information
Summary:The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-2019. Of 327 patients with AML (non-APL) with MRD-results reported in complete remission after two courses of intensive chemotherapy 229 were MRD-negative (70%), as defined by <0.1% cells with leukemia-associated immunophenotype in the bone marrow. MRD-results were reported to clinicians in real time. Multivariate statistical analysis adjusted for known established risk factors did not indicate an association between MFC-MRD and overall survival (HR: 1.00 [95% CI 0.61, 1.63]) with a median follow-up of 2.7 years. Knowledge of the importance of MRD status by clinicians and individualized decisions could have ameliorated the effects of MRD as an independent prognostic factor of overall survival.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1042-8194
1029-2403
1029-2403
DOI:10.1080/10428194.2021.1889539